No distinct YAP1-defined subtype could be distinguished in our cohort, which is consistent with the findings of multiple independent analyses (including those from the investigators originally proposing YAP1 as a candidate subtype)14,17,46, 47, 48 This lack of a unique SCLC-Y subtype might be attributed to tumor heterogeneity,17 therapy-induced plasticity,49,50 and technical controversies regarding the original classification scheme.51 Here, YAP1 is linked to neoplasm.